Table 2.
PK parameters of FT, 5-FU and CDHP in plasma and tears on day 1
| Tmax (h) | T1/2 (h) | Cmax (ng/mL) | AUC0−8 (ng h/mL) | |
|---|---|---|---|---|
| FT | ||||
| Plasma | 1.4 ± 1.1 | 8.5 ± 3.5 | 2046.2 ± 269.3 | 10,786 ± 2556 |
| Tears (right) | 1.6 ± 1.1 | 9.9 ± 7.4 | 2155.5 ± 434.7 | 11,499 ± 1785 |
| Tears (left) | 1.9 ± 1.4 | 10.0 ± 9.2 | 2066.0 ± 334.2 | 11,000 ± 1808 |
| 5-FU | ||||
| Plasma | 2.8 ± 1.0 | 2.6 ± 0.8 | 148.1 ± 91.8 | 768.5 ± 445.7 |
| Tears (right) | 2.9 ± 1.2 | 2.7 ± 1.3 | 232.9 ± 237.5 | 1145.7 ± 1063.3 |
| Tears (left) | 3.1 ± 1.2 | 2.6 ± 1.4 | 228.4 ± 200.7 | 1084.4 ± 855.2 |
| CDHP | ||||
| Plasma | 1.5 ± 1.1 | 3.0 ± 0.7 | 376.5 ± 173.4 | 1340.4 ± 423.1 |
| Tears (right) | 1.9 ± 1.4 | 2.8 ± 1.1 | 240.9 ± 191.6 | 979.4 ± 735.4 |
| Tears (left) | 1.9 ± 1.4 | 2.7 ± 1.1 | 213.9 ± 120.5 | 840.2 ± 492.3 |
FT tegafur; 5-FU 5-fluorouracil; CDHP 5-chloro-2,4-dihydroxypyridine; Cmax Maximum concentration; Tmax Time-to-the-maximum concentration; T1/2 Elimination half-life; AUC0−8 Area under the concentration–time curve from time zero to 8 h point